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Abstract: Background: Co-prescribing medications that can interact with direct-acting oral
anticoagulants (DOACs) may decrease their safety and efficacy. The aim of this study was to
examine the co-prescribing of such medications with DOACs using the Australian national general
practice dataset, MedicineInsight, over a five-year period. Methods: We performed five sequential
cross-sectional analyses in patients with atrial fibrillation (AF) and a recorded DOAC prescription.
Patients were defined as having a drug interaction if they had a recorded prescription of an interacting
medication while they had had a recorded prescription of DOAC in the previous six months.
The sample size for the cross-sectional analyses ranged from 5333 in 2014 to 19,196 in 2018. Results:
The proportion of patients who had potential drug interactions with a DOAC decreased from 45.9%
(95% confidence interval (CI) 44.6%–47.4%) in 2014 to 39.9% (95% CI 39.2%–40.6%) in 2018, p for trend
< 0.001. During this period, the most frequent interacting class of medication recorded as having been
prescribed with DOACs was selective serotonin/serotonin and norepinephrine reuptake inhibitor
(SSRI/SNRI) antidepressants, followed by non-steroidal anti-inflammatory drugs (NSAIDs), calcium
channel blockers (CCBs) and amiodarone. Conclusions: Overall, potential drug interactions with
DOACs have decreased slightly over the last five years; however, the rate of possible interaction with
SSRIs/SNRIs has remained relatively unchanged and warrants awareness-raising amongst prescribers.
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1. Background
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and occurs in about 2%
of the general population [1,2]. Patients with AF are at a higher risk of developing stroke [3]. The newer
direct-acting oral anticoagulants (DOACs) are being used more commonly to prevent ischaemic strokes
and prolong life [4,5]. They are potentially safer, as effective and easier for administration compared
with warfarin [6,7]. However, some medications have pharmacokinetic (PK) or pharmacodynamic
(PD) interactions with DOACs and may decrease their safety and efficacy [8–10].
The absorption and metabolism of DOACs are highly dependent on P-glycoproteins (P-gp)
and cytochrome P450 (CYP) 3A4 enzyme, respectively. The most important classes of drugs that
alter the bioavailability and elimination of DOACs through inhibition of P-gp and CYP3A4 include
macrolide antibiotics (e.g., erythromycin), azole antifungals (e.g., voriconazole) and HIV protease
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inhibitors (e.g., ritonavir) [8,11–13]. The subsequent rise in plasma levels of DOACs increases the risk
of bleeding. Conversely, some antiepileptic medications, such as carbamazepine, decrease the plasma
level of DOACs and their clinical effectiveness by inducing the metabolising enzyme, CYP3A4 [8,14].
In addition, there are PD interactions with DOACs. For instance, non-steroidal anti-inflammatory
drugs (NSAIDs) [8,9], antiplatelet agents [8,15] and selective serotonin/serotonin and norepinephrine
reuptake inhibitors (SSRIs/SNRIs) [8,16] increase the risk of bleeding when co-prescribed with DOACs,
through pharmacological mechanisms.
There have been no large Australian studies investigating potential drug interactions in patients
taking DOACs using real-world data. This study aimed to examine potential drug interactions
in patients with AF taking DOACs over a five-year period.
2. Method
This study was an analysis of retrospective data obtained from the National Prescribing Service
(NPS) MedicineWise dataset. The data were de-identified and extracted from the electronic health
records (EHRs) of general practices across Australia. Details about this dataset can be found
elsewhere [17–19].
2.1. Study Patients
We performed five sequential cross-sectional analyses at the end of each year from 2014 to 2018.
Patients with a recorded diagnosis of AF and at least one DOAC prescription (dabigatran, rivaroxaban
or apixaban) within the census year were included in the analysis. Patients aged <18 years at the end
of the census year or who had had fewer than three visits to the same general practice within two
years (including the census year and the year before the census) were excluded. Patients were defined
as having a drug interaction in the census year if they had a recorded prescription of at least one
interacting medication while they had had a recorded prescription of DOAC in the previous six months.
We assumed a prescription of DOAC covered a maximum of six months.
The co-prescribed medications we searched for included NSAIDs (celecoxib, etoricoxib,
lumiracoxib, parecoxib, rofecoxib, diclofenac, nepafenac, solifenacin, diflunisal, ibuprofen,
indomethacin, ketoprofen, naproxen, sulindac, meloxicam, piroxicam, tenoxicam, ketorolac,
mefenamic acid, flurbiprofen, tiaprofenic acid and phenylbutazone), antiplatelet agents (aspirin,
clopidogrel, ticlopidine, prasugrel, ticagrelor, dipyridamole, abciximab, eptifibatide and tirofiban),
macrolide antibiotics (erythromycin and clarithromycin), oral azole antifungals (ketoconazole,
fluconazole, itraconazole, voriconazole, and posaconazole), HIV protease inhibitors (amprenavir,
atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir and saquinavir),
calcium channel blockers (CCBs) (diltiazem and verapamil), antiarrhythmic agents (amiodarone),
antiepileptics (phenytoin, carbamazepine, valproate, levetiracetam and primidone) and selective
serotonin/norepinephrine reuptake inhibitors (SSRIs/SNRIs) (citalopram, escitalopram, duloxetine,
fluoxetine, paroxetine, fluvoxamine, sertraline, nefazodone, desvenlafaxine and venlafaxine) [11,20].
We obtained ethics approval for this study from the University of Tasmania’s Human Research
Ethics Committee (H0017648). An approval to conduct this study was also obtained from
the MedicineInsight independent Data Governance Committee (2018-033).
2.2. Outcome
The primary outcome of interest was the proportion of patients with a recorded prescription of
DOACs with potential interacting medications.
2.3. Statistical Analysis
The proportion of patients with potential drug interactions was calculated at the end of each year
from 2014 to 2018. We used a Cochran–Armitage test for trend to determine if any observed trends
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were statistically significant. All analyses were performed using SAS software (SAS version 9.4, SAS
Institute Inc., Cary, NC, USA). A two-sided p-value < 0.001 was considered statistically significant.
3. Results
The total number of patients included in each census year ranged from 5333 in 2014 to 19,196
in 2018. The mean age of the 2018 cohort was 76.7 years and 10,410 (54.2%) were males. Overall,
the proportion of patients who had a potential drug interaction with DOAC decreased from 45.9%
(95% confidence interval (CI) 44.6%–47.4%) in 2014 to 39.9% (95% CI 39.2%–40.6%) in 2018, p for trend
<0.001. During this period, the most frequent interacting class of medication prescribed with DOAC
was SSRIs/SNRIs, followed by NSAIDs, CCBs and amiodarone (Figure 1 and Supplementary Materials
Table S1). The proportion of patients who had a CCB interaction with DOACs decreased from 11.3%
(95% CI 10.4%–12.1%) in 2014 to 8.8% (95% CI 8.4%–9.2%) in 2018. The proportion who had an NSAID
interaction over the same period also decreased slightly, from 11.6% (95% CI 10.7%–12.4%) to 9.7%
(95% CI 9.3%–10.1%). The rate of interaction with SSRIs/SNRIs or amiodarone relatively remained
unchanged at approximately 14% and 6%, respectively, over the five-year period.
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Figure 1. Trends in potential drug interactions in patients taking direct-acting oral anticoagulants.
In terms of individual DOACs, 40.0% (1105/2766), 39.1% (3057/7816) and 40.5% (3491/8614) of
patients taking dabigatran, apixaban and rivaroxaban, respectively, were prescribed at least one
concurrent potentially interacting medication in 2018 (Table 1).
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Table 1. Concomitant medications prescribed with direct-acting oral anticoagulants in 2018.
Concomitant Medications Total (n = 19,196) Dabigatran (n = 2766) Rivaroxaban(n = 7816)
Apixaban
(n = 8614)
All interacting medications (%) 7653 (39.9) 1105 (40.0) 3057 (39.1) 3491 (40.5)
Calcium channel blockers (%) 1687 (8.8) 263 (9.5) 684 (8.8) 740 (8.6)
Amiodarone (%) 1250 (6.5) 629 (7.3) 472 (6.0) 629 (7.3)
Azole antifungals (%) 137 (0.7) 18 (0.7) 63 (0.8) 56 (0.7)
Macrolides (%) 548 (2.9) 84 (3.0) 228 (2.9) 236 (2.7)
Antiepileptics (%) 409 (2.1) 57(2.1) 151 (1.9) 201 (2.3)
NSAIDs (%) 1864 (9.7) 275 (9.9) 807 (10.3) 782 (9.1)
Antiplatelet agents (%) 968 (5.0) 145 (5.2) 324 (4.1) 499 (5.8)
SSRIs/SNRIs (%) 2849 (14.8) 408 (14.8) 1141 (14.6) 1300 (15.1)
NSAIDs, non-steroidal anti-inflammatory drugs; SNRIs, selective serotonin and norepinephrine reuptake inhibitors;
SSRIs, selective serotonin reuptake inhibitors.
4. Discussion
This nationwide general practice study shows the following main results. Firstly, some specific
medications advised to be avoided in DOAC users [8,11,21], including SSRIs/SNRIs, NSAIDs and
amiodarone, were commonly prescribed to patients with AF. During 2018, for instance, SSRIs/SNRIs,
NSAIDs and CCBs were co-prescribed with DOACs in 14.8%, 9.7% and 8.8% of DOAC users, respectively.
Secondly, perhaps due to increasing awareness, the rate of potential drug interactions with DOACs
showed a decreasing trend over a five-year period; however, the rate of prescribing SSRIs/SNRIs
was relatively high and remained unchanged. Similarly, a high rate of concomitant SSRIs/SNRI and
DOAC prescribing (22.9%, 22/122) was also reported in a small Australian study of elderly hospitalised
patients by Forbes et al. [22]. Notably, a recent study by Zhang et al. [16], involving almost 24,000 new
users of DOACs in the UK Clinical Practice Research Datalink, found a significant increase in the risk of
major bleeding in patients co-prescribed an SSRI/SNRI (adjusted odds ratio (aOR), 1.68 (95% confidence
interval [CI], 1.10–2.59)) but not with co-prescribed PK-interacting drugs, such as amiodarone. A study
by Quinin et al. [23] also reported that major bleeding was higher in patients taking warfarin during
periods of SSRI exposure compared with periods with warfarin alone (2.32 per 100 person-years,
p < 0.001).
One of the possible explanations for the high proportion of patients co-prescribed an SSRI/SNRI
is a lack of awareness on the interaction of SSRIs/SNRIs with DOAC. There may be a need to
raise prescribers’ awareness of this interaction. The incidence of drug interactions was lower than
in a Taiwanese study [24] by Chang et al. [24], in which diltiazem and amiodarone were used in more
than 20% of DOAC-exposed person-quarters (exposure time for each person during each quarter of
the calendar year). A possible explanation for this difference might be our use of more recent data,
as compared with 2012–2016 data for the Taiwanese study.
Strengths and Limitations
This is the first Australian study that evaluated potential drug interactions in patients prescribed
DOACs, using the largest general practice dataset available to researchers. Busingye et al. [25]
investigated the national representativeness of the NPS MedicineWise dataset. While South Australia
was underrepresented and Tasmania and New South Wales were overrepresented, the dataset was
representative in terms of the age and gender of the participants based on comparisons with national
Medical Benefits Schedule data. Although we only included regular general practice patients who had at
least three visits within two years in each cross-sectional analysis, it is possible that interacting medicines
were prescribed by other general practices or specialists and not recorded in the MedicineInsight
dataset. The use of aspirin or NSAIDs is not routinely recorded in the dataset, as many patients
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obtain them without a prescription. Patients were defined as having a drug interaction if they had
a recorded prescription of an interacting medication while they had had a recorded prescription of
DOAC in the previous six months. As a result, it is possible that the DOAC had been ceased prior to
the actual commencement of the interacting drug.
This study did not have clinical outcome data, such as bleeding and ischaemic stroke, associated
with the potential drug interactions. However, elsewhere, patients who were prescribed the selected
interacting medications for this study with DOACs were found to experience major bleeding or
ischaemic stroke [14,16,24]. It should be noted that the rates alone of co-prescribing of potentially
interacting drugs do not necessarily correlate with the risk of major adverse events. For instance,
although the rate of co-prescribing macrolides and azole antifungals with DOACs was low (i.e., 2.9%
and 0.7%, respectively, for 2018), the risk for clinically severe consequences could have been high, based
on their PK interactions. Similarly, the duration of co-prescription of interacting medications would
influence the risk of significant adverse events arising. For instance, SSRIs/SNRIs are co-prescribed
with DOACs mostly for long-term conditions, and this may partly explain the observed increased
risk of bleeding with these drugs. It might also partly explain why the co-prescribing of SSRIs/SNRIs
remained relatively constant, in comparison with drugs more commonly used short-term (e.g., NSAIDs)
over the course of the study.
5. Conclusions
Overall, potential drug interactions with DOACs have decreased slightly over the last five years;
however, the rate of possible interaction with SSRIs/SNRIs has remained relatively unchanged and
may warrant awareness-raising amongst prescribers.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/11/3568/s1,
Table S1. Trends in potential drug interactions with DOACs in patients with atrial fibrillation.
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